Human Cell Co
Naperville, IL
- UEI
- F4N9XZWABV33
- CAGE
- 794C3
- Primary NAICS
- Not on record
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 1701 Quincy Ave #21, Naperville, IL 60540, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Topical treatment of an optimized NGF for dry eye - project summary dry eye disease (DED) is an increasingly frequency… | National Eye Institute | $730,000 | |
| Topical NGF therapy and oral nicotinamide supplementation for glaucoma - abstract glaucoma is a leading cause of… | National Eye Institute | $360,897 | |
| Optimization of TIL cell manufacturing for cancer treatment - abstract adoptive cell therapy (act) using autologous… | National Cancer Institute | $400,000 | |
| TPA and NGF therapy for stroke - principal investigator/program director (last, first, middle: soon seog jeong… | National Institute of Neurological Disorders and Stroke | $1,078,500 | |
| Recombinant prothrombin therapy for hemorrhage | National Heart Lung and Blood Institute | $299,575 |
About Human Cell Co
Human Cell Co is a for-profit corporate entity registered in the federal System for Award Management (SAM.gov) since November 2014, with an active registration until August 2025. The company specializes in biotechnology research and development, focusing on advanced therapeutic approaches for neurological and ophthalmological conditions. While specific details about the company's full organizational structure are not provided, their federal grant awards suggest they are a research-focused biotech firm with expertise in developing novel protein therapies, particularly around nerve growth factor (NGF) modifications and innovative treatment strategies.
The company has received multiple prime federal grant awards from civilian agencies, primarily focusing on translational medical research in ophthalmology and neuroscience. Notably, Human Cell Co has secured substantial research grants from the National Eye Institute and the National Institute of Neurological Disorders and Stroke, totaling over $1 million in recent awards. Their research projects include developing optimized nerve growth factor (NGF) therapies for conditions such as glaucoma, dry eye disease, and stroke recovery. The grants demonstrate the company's commitment to developing innovative therapeutic approaches, including a proprietary NGF mutein (HC201) designed to improve receptor binding and cellular response. Their research spans preclinical and translational studies, with specific aims of improving treatment outcomes for complex medical conditions by exploring novel protein modifications, combination therapies, and advanced cellular manufacturing techniques for treatments like tumor-infiltrating lymphocyte (TIL) cell therapy.
Quick answers
What is Human Cell Co's UEI?
Human Cell Co's Unique Entity ID (UEI) in SAM.gov is F4N9XZWABV33.
What is Human Cell Co's CAGE code?
Human Cell Co's CAGE code is 794C3.
Where is Human Cell Co located?
Human Cell Co's physical address in SAM.gov is 1701 Quincy Ave #21, Naperville, IL 60540, USA.
Is Human Cell Co registered in SAM.gov?
Yes. Human Cell Co's SAM.gov registration is active through July 30, 2027.
What is Human Cell Co's most recent federal award?
Human Cell Co's most recent federal grant award is Topical treatment of an optimized NGF for dry eye - project summary dry eye disease (DED) is an increasingly frequency… (R43EY036298), from National Eye Institute, on September 30, 2024.
On GovTribe
See Human Cell Co's full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors